---
schema_version: "secwatch.filing_event.v1"
accession: "0001698530-23-000026"
form_type: "8-K"
ticker: "XCUR"
cik: "0001698530"
company_name: "EXICURE, INC."
filed_at: "2023-03-27T23:59:59+00:00"
generated_at: "2026-06-17T15:09:41.823513+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Exicure FY2022 net loss $2.6M, revenue $28.8M non-cash; R&D halted; going concern warning

## Summary
- Net loss of $2.6M for FY2022 vs $64.1M loss in 2021; revenue $28.8M from non-cash recognition of deferred revenue after AbbVie and Ipsen terminations.
- Cash and equivalents $9.8M at 12/31/22; subsequent private placement raised $5.4M gross ($4.6M net); cash expected into Q4 2023.
- Going concern: substantial doubt about ability to continue; need additional financing within next few months.
- R&D expense down 60% to $19.8M; company halted all R&D and reduced workforce in September 2022.
- CBI USA became majority owner (50.4%) after private placement; board expanded to 6, with only one prior director remaining; controlled company exemption.

## SEC filing metadata
- accession: 0001698530-23-000026
- form_type: 8-K
- ticker: XCUR
- cik: 0001698530
- company_name: EXICURE, INC.
- filed_at: 2023-03-27T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1698530/000169853023000026/0001698530-23-000026-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1698530/000169853023000026/xcur-20230327.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001698530-23-000026
- JSON: https://secwatch.observer/filing/0001698530-23-000026.json
- Plain text: https://secwatch.observer/filing/0001698530-23-000026.txt

## Key facts
- Earnings Releases
  EXICURE, INC. reported the year ended December 31, 2022 results: revenue $28.8 million.
  - Period: the year ended December 31, 2022
  - Revenue: $28.8 million
  - Result: reported results
  source text: status of the Company as it explores strategic alternatives and this estimate may prove inaccurate and the Company may expend its limited resources sooner. Revenue : Revenue was $28.8 million for the year ended December 31, 2022, reflecting an increase of $29.3 million from revenue of $(0.5) million for the year ended December 31, 2021. The increase in collaboration
  evidence_url: https://www.sec.gov/Archives/edgar/data/1698530/000169853023000026/0001698530-23-000026-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.